Lifestyle Intervention of Food and Exercise for Lymphoma Survivors (LIFE - L)

Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to investigate if a mediterranean diet and exercise program for Lymphoma patients during chemotherapy can improve treatment completion and reduce treatment-related side effects.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• 18 years of age or older

• Any sex/gender

• Able to provide consent

• Able to read or understand English or Spanish

• Diagnosis of untreated Non-Hodgkin or Hodgkin lymphoma, requiring at least 6 cycles of chemotherapy, being treated with one of the following therapies at discretion of PIs:

∙ R-CHOP or R-CHOP-like regimen

‣ BR

‣ BV-AVD or ABVD or checkpoint inhibitor+AVD

• ECOG Performance Status grade of \<2

• a. PI approval needed if ECOG = 2

• Approval from treating oncologist, confirmed via email or in writing

• Delivery of chemotherapy treatments at one of the following institutions:

∙ Sylvester Comprehensive Cancer Center (including satellite/network sites)

‣ University of Miami Hospital/UHealth Tower

• Internet access on a smart phone, tablet, or computer

⁃ Willing to be randomized to a Mediterranean diet/home-based physical activity intervention or waitlist-control group.

Locations
United States
Florida
University of Miami
RECRUITING
Miami
Contact Information
Primary
Tracy E Crane, PhD, RDN
tecrane@med.miami.edu
305-243-8255
Time Frame
Start Date: 2023-04-26
Estimated Completion Date: 2026-01-31
Participants
Target number of participants: 120
Treatments
Experimental: LIFE-L Group
Participants already undergoing chemotherapy treatment as per standard of care for 6 cycles will meet weekly via phone for 30-45 minutes with a health coach that will provide education on a Mediterranean diet and an exercise program.
Other: Control Group
Participants in this group already undergoing 6 cycles of chemotherapy will receive study materials and two 30-45 minutes health coaching sessions four weeks post- intervention.
Related Therapeutic Areas
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Sponsors
Leads: University of Miami

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies

Enrollment Status: Recruiting
Publish Date: October 30, 2025
Intervention Type: Drug
Study Phase: Phase 1

Interest of Individual Biomarkers From the Identification of Tumor Genotype in Plasma (ctDNA: Circulating Tumor DNA) by High-throughput Molecular Next Generation Techniques(CAPP Seq, PhAsE Seq, VIRCAPP-seq) in the Diagnosis and Personalized Management of Lymphomas in a Prospective Monocentric Cohort

Interest of Individual Biomarkers From the Identification of Tumor Genotype in Plasma (ctDNA: Circulating Tumor DNA) by High-throughput Molecular Next Generation Techniques(CAPP Seq, PhAsE Seq, VIRCAPP-seq) in the Diagnosis and Personalized Management of Lymphomas in a Prospective Monocentric Cohort

Enrollment Status: Recruiting
Publish Date: June 11, 2025
Intervention Type: Biological
Study Phase: Not Applicable

Early Assessment of Aggressive B-Cell Lymphoma Treatment Response and Prediction of Recurrence Using Phased Variant Analysis With Next-Generation Sequencing

Early Assessment of Aggressive B-Cell Lymphoma Treatment Response and Prediction of Recurrence Using Phased Variant Analysis With Next-Generation Sequencing

Enrollment Status: Recruiting
Publish Date: June 17, 2025
Intervention Type: Diagnostic test
View All